𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Malignant leydig cell tumor: Objective tumor response to o, p′-DDD

✍ Scribed by Paul C. Azer; Glenn D. Braunstein

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
567 KB
Volume
47
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Malignant leydig cell tumor: Clinical, h
Malignant leydig cell tumor: Clinical, histologic and electron microscopic features
✍ P. S. Feldman; K. Kovacs; E. Horvath; G. L. Adelson 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 970 KB

A 51-year-old man had a malignant Leydig cell tumor of the testis with elevation of serum estrone and endrostenedione as well as urine chorionic gonadotropin. The fine structural features of the neoplasm resembled those of nontumorous Leydig cells as well as cells of Leydig cell adenomas, except for

Fine-needle aspiration biopsy of maligna
Fine-needle aspiration biopsy of malignant testicular Leydig (interstitial) cell tumor
✍ P. Göran Elmberger; Brian T. Collins 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 2 views

Dear Dr. Bedrossian: Leydig (interstitial) cell tumors are rare neoplasms accounting for 1-3% of all testicular tumors. Only 10% of these neoplasms will demonstrate malignant behavior, characterized by metastases to retroperitoneal lymph nodes, lung, and liver. While rare primary Leydig cell tumors

P53-specific T cell responses in patient
P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy
✍ Annechien Lambeck; Ninke Leffers; Baukje-Nynke Hoogeboom; Wim Sluiter; Ineke Ham 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 214 KB

## Abstract Despite intensive treatment, 70% of the ovarian cancer patients will develop recurrent disease, emphasizing the need for new approaches such as immunotherapy. A promising antigenic target for immunotherapy in ovarian cancer is the frequently overexpressed p53 protein. The aim of the stu